ARHGEF2 and neoplasm: Rocaglates are a class of compounds, initially thought to be eIF4A antagonist, that exhibit potential in cancer therapy and protect against multiple infections, inducing GEF-H1 protein expression and JNK phosphorylation in tumor cells, triggering tumor cell death without affecting healthy organs (31).